Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (1091)	12/3/1999 2:15:00 PM
From: scaram(o)uche	Respond to of 4974

Thanks.... last time you addressed me and my concept of rationale, munch thread, this was my answer........ Subject: Munch-a-Biotech Today To: software salesperson From: Richard Harmon Feb 23 1999 6:56PM EST Reply #198 of 757 Sure.... I consider MLNM to be one of the top four drug discovery engines in the world, and the milestones keep rolling out to complement the Bayer deal. Had the op to visit recently with Jim Silverman and to get, among other detailed peeks, a look at proteomics. Good stuff. Review the MLNM thread for more comments. (snip) Drug development costs money, and the infrastructure and patents required to do such are valuable. One places their own personal value on them. I look at biologicals that do $1 billion/year and pharmaceuticals that do better, and see a market cap of $1.3 billion as a pittance.